Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
KZIA 
Kazia Therapeutics Ltd ADR (KZIA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: KZIA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -44.12% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.47M USD | Price to earnings Ratio - | 1Y Target Price 2.94 |
Price to earnings Ratio - | 1Y Target Price 2.94 | ||
Volume (30-day avg) 264997 | Beta 2.29 | 52 Weeks Range 0.76 - 15.80 | Updated Date 04/2/2025 |
52 Weeks Range 0.76 - 15.80 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -789.14% |
Management Effectiveness
Return on Assets (TTM) -71.63% | Return on Equity (TTM) -2634.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3814069 | Price to Sales(TTM) 1.8 |
Enterprise Value 3814069 | Price to Sales(TTM) 1.8 | ||
Enterprise Value to Revenue 2.63 | Enterprise Value to EBITDA -0.71 | Shares Outstanding 5589290 | Shares Floating 434055007 |
Shares Outstanding 5589290 | Shares Floating 434055007 | ||
Percent Insiders - | Percent Institutions 5.24 |
Analyst Ratings
Rating 4 | Target Price 1.99 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kazia Therapeutics Ltd ADR
Company Overview
History and Background
Kazia Therapeutics Ltd is an Australian oncology-focused drug development company, formerly known as Novogen. Founded in 1995, it initially focused on anti-cancer compounds derived from natural sources. Over time, it shifted its focus to developing small molecule inhibitors for various cancer targets. The company is listed on the Australian Securities Exchange (ASX) and has an ADR program in the US.
Core Business Areas
- Oncology Drug Development: Focuses on discovering, developing, and commercializing innovative therapies for cancer. Primarily involved in clinical trials for its lead compounds.
Leadership and Structure
Kazia Therapeutics Ltd is led by a board of directors and an executive management team. The CEO is responsible for the overall strategy and operations of the company. The organizational structure includes departments for research and development, clinical operations, regulatory affairs, and commercial strategy.
Top Products and Market Share
Key Offerings
- Paxalisib: Paxalisib is a PI3K / Akt / mTOR pathway inhibitor being developed for glioblastoma and other cancers. Currently, it is undergoing clinical trials. Market share data is not currently available due to its development stage. Competitors include companies developing similar PI3K inhibitors and standard-of-care chemotherapy treatments.
- Cantrixil: Cantrixil is an investigational small molecule being developed for ovarian cancer. Currently, it is undergoing clinical trials. Market share data is not currently available due to its development stage. Competitors include companies developing similar ovarian cancer treatments and standard-of-care chemotherapy treatments.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly oncology, is characterized by intense competition, high regulatory hurdles, and significant investment in research and development. The market is driven by the increasing prevalence of cancer, advancements in personalized medicine, and the development of novel therapies.
Positioning
Kazia Therapeutics Ltd ADR is a small-cap biotech company focused on developing innovative oncology therapies. Its competitive advantages lie in its proprietary drug candidates and targeted approach to cancer treatment. However, it faces competition from larger, more established pharmaceutical companies with greater resources.
Total Addressable Market (TAM)
The global oncology market is estimated to be in the hundreds of billions of dollars. Kazia Therapeutics Ltd ADR is positioned to capture a portion of this TAM with its lead compounds, particularly if they demonstrate clinical efficacy and receive regulatory approval. The specific market share will depend on factors such as clinical trial outcomes, regulatory approvals, and commercialization strategies.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates with novel mechanisms of action
- Experienced management team with expertise in drug development
- Focused strategy on oncology
- Strong intellectual property protection for its drug candidates
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk of clinical trial failure
- Dependence on successful development and commercialization of its drug candidates
- Small market capitalization and trading volume
Opportunities
- Potential for breakthrough therapies in areas with unmet medical needs
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new indications for its drug candidates
- Positive clinical trial results leading to regulatory approval
Threats
- Competition from larger pharmaceutical companies with greater resources
- Failure to achieve positive clinical trial results
- Regulatory hurdles and delays
- Patent challenges and infringement
Competitors and Market Share
Key Competitors
- BMY
- MRK
- NVS
- PFE
- AZN
Competitive Landscape
Kazia Therapeutics Ltd ADR faces significant competition from larger, more established pharmaceutical companies with greater resources and broader pipelines. Its advantages lie in its focused strategy and proprietary drug candidates, but it must navigate a challenging competitive landscape.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of its drug candidates through clinical trials and securing partnerships. Growth is often measured by its clinical trial progress.
Future Projections: Future growth is highly dependent on the successful development and commercialization of its drug candidates. Analyst estimates vary widely and are subject to change based on clinical trial results.
Recent Initiatives: Recent initiatives include advancing paxalisib and cantrixil through clinical trials, seeking strategic partnerships, and exploring new indications for its drug candidates.
Summary
Kazia Therapeutics Ltd ADR is a clinical-stage oncology company with potential in its lead drug candidates, particularly paxalisib. Its financial performance is dependent on clinical trial progress and partnerships. The company faces significant risks associated with clinical trial failure and competition. Positive clinical data is crucial for its success and shareholder returns. They need to be aware of threats from larger pharmaceutical companies and competition from novel therapies.
Similar Companies
AZN
AstraZeneca PLC ADR
AZN
AstraZeneca PLC ADR
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and due diligence. Market share data is an estimate. The company data is dynamic and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kazia Therapeutics Ltd ADR
Exchange NASDAQ | Headquaters Sydney, NSW, Australia | ||
IPO Launch date 1999-01-06 | CEO, MD & Director Dr. John Edwin Friend II, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | |
Full time employees - | |||
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.